STOCK TITAN

4D Molecular (NASDAQ: FDMT) CLO exercises options, sells 9,810 shares at $12

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

4D Molecular Therapeutics Chief Legal Officer Scott Bizily reported an exercise-and-sell stock transaction. On June 23, 2026, he exercised options to acquire 9,810 shares of common stock at $4.14 per share, then sold 9,810 shares in an open-market trade at $12.00 per share.

After these transactions, he holds 18,427 common shares directly and 63,785 stock options with a $4.14 exercise price expiring in 2035. A footnote also notes 5,023 shares previously purchased under the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

Positive

  • None.

Negative

  • None.
Insider Bizily Scott
Role Chief Legal Officer
Sold 9,810 shs ($118K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 9,810 $0.00 --
Exercise Common Stock 9,810 $4.14 $41K
Sale Common Stock 9,810 $12.00 $118K
Holdings After Transaction: Stock Option (Right to Buy) — 63,785 shares (Direct, null); Common Stock — 18,427 shares (Direct, null)
Footnotes (1)
  1. Reflects 5,023 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Shares sold 9,810 shares Open-market sale of common stock on June 23, 2026 at $12.00
Sale price $12.00 per share Price for 9,810 common shares sold on June 23, 2026
Options exercised 9,810 shares Common stock acquired via option exercise at $4.14 per share
Exercise price $4.14 per share Stock option exercise price for 9,810 underlying shares
Shares held after 18,427 shares Direct common stock ownership after transactions
Options remaining 63,785 options Stock options outstanding after exercise, expiring March 5, 2035
ESPP shares 5,023 shares Common stock purchased under Employee Stock Purchase Plan, Rule 16b-3 exempt
Employee Stock Purchase Plan financial
"Reflects 5,023 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3 regulatory
"purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
Vesting Commencement Date financial
"on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bizily Scott

(Last)(First)(Middle)
C/O 4D MOLECULAR THERAPEUTICS, INC.
5858 HORTON STREET #455

(Street)
EMERYVILLE CALIFORNIA 94608

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/23/2026M9,810A$4.1418,427(1)D
Common Stock06/23/2026S9,810D$128,617D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.1406/23/2026M9,810 (2)03/05/2035Common Stock9,810$063,785D
Explanation of Responses:
1. Reflects 5,023 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
/s/ Scott Bizily06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

How many FDMT shares does Scott Bizily hold after the reported Form 4 transactions?

Following the June 23, 2026 transactions, Scott Bizily holds 18,427 shares of 4D Molecular Therapeutics common stock directly. This figure comes from the post‑transaction ownership column associated with the non‑derivative holdings in the Form 4 data.

What does the FDMT Form 4 say about shares bought under the Employee Stock Purchase Plan?

A footnote states that 5,023 FDMT shares were purchased under the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b‑3. This clarifies that those shares were acquired through a qualified employee plan rather than open‑market trading.